https://doi.org/10.4081/monaldi.2018.961
Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation
Accepted: May 11, 2018
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non–vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selection and use of OAC in older adults to aid clinical decision making.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Filippo Brandimarte, Alessandro Battagliese, Silvana Petronilla Pirillo, Maria Teresa Mallus, Rosa Maria Manfredi, Giovanni Carreras, A case of arrhythmogenic right ventricular cardiomyopathy with biventricular involvement , Monaldi Archives for Chest Disease: Vol. 89 No. 1 (2019)
You may also start an advanced similarity search for this article.
